Montelukast in the management of allergic rhinitis

(2503) Views  (636) Full article downloads

Authors: Jaime A Lagos, Gailen D Marshall

Published Date May 2007 Volume 2007:3(2) Pages 327 - 332

DOI: http://dx.doi.org/10.2147/TCRM.S

Jaime A Lagos, Gailen D Marshall

Division of Clinical Immunology and Allergy, University of Mississippi Medical Center, Jackson, MS, USA

Abstract: Allergic rhinitis is the most common atopic disorder seen in the outpatient clinic setting diagnosed by history, physical exam and objective testing. According to the Allergic Rhinitis and its Impact on Asthma (ARIA) document, it is classified by chronicity (intermittent or persistent), and severity which is based on symptoms and quality of life (mild, or moderate/severe). It has enormous socioeconomic costs and significant reduction in quality of life. Allergen avoidance should be implemented, particularly in children, to reduce level of exposure; unfortunately efforts are often inadequate. Montelukast, a novel medication, is an antagonist to the leukotriene receptor. It is nonsedating, dosed once daily, and has a safety profile similar in adults and children with approval down to 6 months of age. A review of the literature undoubtedly establishes montelukast as a viable alternative for the treatment of seasonal allergic rhinitis. Its benefits are equivalent to antihistamines, when used as monotherapy, but less than intranasal corticosteroids. The addition of an antihistamine to montelukast does appear to have added benefits and at times is reported to be equivalent to intranasal corticosteroids.

Keywords: allergic rhinitis, montelukast, management, drug therapy